These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1079317)

  • 1. Letter: Methotrexate-citrovorum factor in treating osteogenic sarcoma.
    Djerassi I
    N Engl J Med; 1975 May; 292(21):1133-4. PubMed ID: 1079317
    [No Abstract]   [Full Text] [Related]  

  • 2. [High-dose methotrexate with citrovorum factor rescue in osteogenic carcinoma].
    Levi M; Sulkes A; Katz E; Rizel S; Biran S
    Harefuah; 1980 Sep; 99(5-6):110-3. PubMed ID: 6970707
    [No Abstract]   [Full Text] [Related]  

  • 3. High-dose methotrexate with citrovorum factor in osteogenic sarcoma--progress report II.
    Jaffe N; Frei E; Traggis D; Cassady JR; Watts H; Filler RM
    Cancer Treat Rep; 1977 Jul; 61(4):675-9. PubMed ID: 301780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Single"-agent activity of high-dose methotrexate with citrovorum factor rescue.
    Von Hoff DD; Rozencweig M; Louie AC; Bender RA; Muggia FM
    Cancer Treat Rep; 1978 Feb; 62(2):233-5. PubMed ID: 305823
    [No Abstract]   [Full Text] [Related]  

  • 5. Osteogenic sarcoma: state of the art with high-dose methotrexate treatment.
    Jaffe N
    Clin Orthop Relat Res; 1976 Oct; (120):95-102. PubMed ID: 1086179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress report on high-dose methotrexate (NSC-740) with citrovorum rescue in the treatment of metastatic bone tumors.
    Jaffe N
    Cancer Chemother Rep; 1974; 58(2):275-80. PubMed ID: 4598245
    [No Abstract]   [Full Text] [Related]  

  • 7. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma.
    Jaffe N; Frei E; Traggis D; Bishop Y
    N Engl J Med; 1974 Nov; 291(19):994-7. PubMed ID: 4606174
    [No Abstract]   [Full Text] [Related]  

  • 8. High-dose methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcoma.
    Rosen G; Suwansirikul S; Kwon C; Tan C; Wu SJ; Beattie EJ; Murphy ML
    Cancer; 1974 Apr; 33(4):1151-63. PubMed ID: 4544836
    [No Abstract]   [Full Text] [Related]  

  • 9. High-dose methotrexate in osteogenic sarcoma: a 5-year experience.
    Jaffe N; Frei E; Watts H; Traggis D
    Cancer Treat Rep; 1978 Feb; 62(2):259-64. PubMed ID: 346215
    [No Abstract]   [Full Text] [Related]  

  • 10. Patient case involving high-dose methotrexate followed by leucovorin rescue.
    Alsop JA
    Am J Hosp Pharm; 1978 Feb; 35(2):127. PubMed ID: 305201
    [No Abstract]   [Full Text] [Related]  

  • 11. [Management of the administration of leucovorin calcium in high-dose methotrexate therapy].
    Kickinger W; Ritschl P; Kotz R
    Arzneimittelforschung; 1989 Jun; 39(6):728-31. PubMed ID: 2789050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose methotrexate for the patient with osteogenic sarcoma.
    Nirenberg A
    Am J Nurs; 1976 Nov; 76(11):1776-80. PubMed ID: 136192
    [No Abstract]   [Full Text] [Related]  

  • 13. [H-MTX-CF treatment and osteogenic sarcoma (author's transl)].
    Goto M
    Hokkaido Igaku Zasshi; 1981 Mar; 56(2):235. PubMed ID: 6976923
    [No Abstract]   [Full Text] [Related]  

  • 14. Letter: Limitations of methotrexate and citrovorum-factor treatment.
    Frei E; Jaffe NJ; Pitman S
    N Engl J Med; 1975 Jan; 292(2):107-8. PubMed ID: 1078551
    [No Abstract]   [Full Text] [Related]  

  • 15. High-dose methotrexate therapy with citrovorum factor: a pharmacologic perspective in murine tumor models.
    Sirotnak FM; Donsbach RC; Dorick DM; Moccio DM
    Cancer Treat Rep; 1977 Jul; 61(4):565-74. PubMed ID: 301778
    [No Abstract]   [Full Text] [Related]  

  • 16. High-dose methotrexate with citrovorum factor rescue: predictive value of serum methotrexate concentrations and corrective measures to avert toxicity.
    Nirenberg A; Mosende C; Mehta BM; Gisolfi AL; Rosen G
    Cancer Treat Rep; 1977 Aug; 61(5):779-83. PubMed ID: 302143
    [No Abstract]   [Full Text] [Related]  

  • 17. Transient cerebral dysfunction following chemotherapy for osteogenic sarcoma.
    Allen JC; Rosen G
    Ann Neurol; 1978 May; 3(5):441-4. PubMed ID: 310278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy for osteogenic sarcoma: an investigative method, not a recipe.
    Rosen G; Nirenberg A
    Cancer Treat Rep; 1982 Sep; 66(9):1687-97. PubMed ID: 6981454
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostic factors in the response of primary osteogenic sarcoma to preoperative chemotherapy (high-dose methotrexate with citrovorum factor).
    Juergens H; Kosloff C; Nirenberg A; Mehta BM; Huvos AG; Rosen G
    Natl Cancer Inst Monogr; 1981 Apr; (56):221-6. PubMed ID: 6975439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of high-dose methotrexate with citrovorum factor "rescue" in the treatment of osteogenic sarcoma.
    Jaffe N; Traggis D; Cassady JR; Filler RM; Watts H; Frei E
    Int J Radiat Oncol Biol Phys; 1977; 2(3-4):261-6. PubMed ID: 301137
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.